Spanish Journal of Psychiatry and Mental Health最新文献

{"title":"Tobacco use disorder and other mental disorders: The neglected dual disorder","authors":"Carlos Parro-Torres , Miquel Casas , José Martínez-Raga , Ma Cristina Pinet Ogué , Pilar Alejandra Sáiz Martínez , Néstor Szerman","doi":"10.1016/j.sjpmh.2024.04.002","DOIUrl":"10.1016/j.sjpmh.2024.04.002","url":null,"abstract":"","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 67-69"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Theory of Mind as an endophenotype for schizophrenia spectrum disorder: Study in first episode of psychosis patients and first-degree relatives","authors":"Georgelina Abreu-Fernández ,&nbsp;Nancy Murillo-García ,&nbsp;Víctor Ortiz-García de la Foz ,&nbsp;Rebeca Magdaleno Herrero ,&nbsp;Ángel Yorca-Ruiz ,&nbsp;Rosa Ayesa-Arriola","doi":"10.1016/j.sjpmh.2023.09.004","DOIUrl":"10.1016/j.sjpmh.2023.09.004","url":null,"abstract":"<div><h3>Background</h3><div><span>Deficits in Theory of Mind (ToM) had been suggested as a possible </span>endophenotype for unaffected relatives of first episode of psychosis (FEP) patients. There are a limited number of studies which have evaluated ToM deficits among the siblings and parents of FEP patients.</div></div><div><h3>Aim</h3><div>This study aimed to explore ToM deficits and its correlates among FEP patients, their siblings, parents, and controls.</div></div><div><h3>Methodology</h3><div>FEP patients (<em>N</em> <!-->=<!--> <!-->102), their parents (<em>N</em> <!-->=<!--> <!-->135), siblings (<em>N</em> <!-->=<!--> <!-->97), and controls (<em>N</em> <!-->=<!--> <!-->167) were evaluated on ToM performance with the Reading the Mind in the Eyes Test (Eyes Test). Interview for sociodemographic variables of age, sex, years of education, and IQ estimation and neurocognitive tests were administered to all groups.</div></div><div><h3>Results</h3><div>FEP patients had a significantly lower performance on the Eyes Test compared to their siblings and controls. However, no significant differences were found between siblings and parents or siblings and controls.</div></div><div><h3>Conclusion</h3><div>Attending our results, we found no evidence for ToM deficits as an endophenotype of SSDs. Furthermore, ToM accuracy may be mediated by interaction with other cognitive domains and play a protective role against psychosis in unaffected siblings.</div></div>","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 100-105"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135706848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased risk of early lung function alterations in people with psychosis: A cross-sectional case–control study","authors":"Ana Viejo Casas ,&nbsp;Carlos Amado Diago ,&nbsp;Juan Agüero Calvo ,&nbsp;Marcos Gómez-Revuelta ,&nbsp;Paula Suarez Pinilla ,&nbsp;Claudia Ovejas Catalán ,&nbsp;Paloma Fuentes Pérez ,&nbsp;Mario Ruiz Núñez ,&nbsp;Roberto Garrastazu López ,&nbsp;María Juncal Ruiz ,&nbsp;Benedicto Crespo-Facorro ,&nbsp;Javier Vázquez-Bourgon","doi":"10.1016/j.sjpmh.2023.10.004","DOIUrl":"10.1016/j.sjpmh.2023.10.004","url":null,"abstract":"<div><h3>Background</h3><div>Tobacco smoking has been described as the main cause of chronic obstructive pulmonary disease (COPD) and this habit is clearly more frequent among individuals with psychosis than in the general population, with rates reaching up to 60%. However, little attention has been focused on the association of COPD and psychosis. We aimed to explore the risk of presenting early lung function alterations in a group of individuals with psychosis.</div></div><div><h3>Methods</h3><div>Following an observational cross-sectional design we studied a cohort of individuals with established psychosis (<em>N</em> <!-->=<!--> <!-->128), and compared them with a sex, age, and smoking habit matched control group (<em>N</em> <!-->=<!--> <span>79). We evaluated respiratory symptoms by means of mMRC<span>, CAT and Dyspnea-12 scales. And lung function through spirometry tests.</span></span></div></div><div><h3>Results</h3><div><span>Individuals with psychosis presented more respiratory symptoms than controls. Similarly, we observed significant differences in the lung function tests between these two groups, where individuals with psychosis presented worse results in most of the spirometry mean values (FEV</span>₁ or forced expiratory volume in the first one second: 3.29<!--> <!-->L vs. 3.75<!--> <!-->L, <em>p</em> <!-->&lt;<!--> <span>0.001; forced vital capacity or FVC: 4.25</span> <!-->L vs. 4.72<!--> <!-->L, <em>p</em> <!-->=<!--> <!-->0.002; and FEV₁/FVC ratio: 0.78 vs. 0.80, <em>p</em> <!-->=<!--> <span><span>0.052). Patients also presented worse values of lung diffusion<span>, with lower diffusing capacity for </span></span>carbon monoxide (DLCO) than controls (6.95 vs. 8.54</span> <!-->mmol/min/kPa, <em>p</em> <!-->&lt;<!--> <!-->0.001).</div></div><div><h3>Conclusions</h3><div>The individuals with psychosis in our study presented greater respiratory symptoms and poorer lung function measured through spirometry. These signs have been described as early signs of COPD.</div></div>","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 111-115"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138296890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term trajectories of clinical staging in first-episode psychosis and their associated cognitive outcome: A 21-year follow-up study","authors":"Manuel J. Cuesta ,&nbsp;Ana M. Sánchez-Torres ,&nbsp;Lucia Moreno-Izco ,&nbsp;Elena García de Jalón ,&nbsp;Gustavo J. Gil-Berrozpe ,&nbsp;Victor Peralta","doi":"10.1016/j.sjpmh.2024.02.001","DOIUrl":"10.1016/j.sjpmh.2024.02.001","url":null,"abstract":"<div><div>Cognitive deficits are already present before psychosis onset but are a key feature of first-episode psychosis (FEP). The objective of this study was to investigate the cognitive outcomes of a cohort of FEP patients who were diagnosed using the clinical staging approach and were followed for up to 21 years.</div><div>We analyzed data from 173 participants with first-admission psychosis who were followed-up for a mean of 20.9 years. The clinical staging assessment was adapted from the clinical staging framework developed by McGorry et al.<span><span>¹</span></span> Cognitive assessment was performed using the MATRICS Consensus Cognitive Battery (MMCB) at the end of follow-up.</div><div>FEP patients who were longitudinally diagnosed in the lowest clinical stages (stages 2A and 2B) showed better performance in attention, processing speed, and MCCB overall composite score than those in the highest clinical stages (stages 4A and 4B). There was a significant linear trend association between worsening of all MCCB cognitive functions and MCCB overall composite score and progression in clinical staging. Furthermore, the interval between two and five years of follow-up appears to be associated with deficits in processing speed as a cognitive marker.</div><div>Our results support the validation of the clinical staging model over a long-term course of FEP based on neuropsychological performance. A decline in some cognitive functions, such as processing speed, may facilitate the transition of patients to an advanced stage during the critical period of first-episode psychosis.</div></div>","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 116-124"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Negative symptoms and sex differences in first episode schizophrenia: What's their role in the functional outcome? A longitudinal study","authors":"Silvia Amoretti ,&nbsp;Gisela Mezquida ,&nbsp;Norma Verdolini ,&nbsp;Miquel Bioque ,&nbsp;Ana M. Sánchez-Torres ,&nbsp;Laura Pina-Camacho ,&nbsp;Iñaki Zorrilla ,&nbsp;Amira Trabsa ,&nbsp;Roberto Rodriguez-Jimenez ,&nbsp;Iluminada Corripio ,&nbsp;Salvador Sarró ,&nbsp;Angela Ibañez ,&nbsp;Judith Usall ,&nbsp;Rafael Segarra ,&nbsp;Eduard Vieta ,&nbsp;Natalia Roberto ,&nbsp;Josep Antoni Ramos-Quiroga ,&nbsp;Alfonso Tortorella ,&nbsp;Giulia Menculini ,&nbsp;Manuel J. Cuesta ,&nbsp;M. Paz Portilla","doi":"10.1016/j.sjpmh.2023.04.001","DOIUrl":"10.1016/j.sjpmh.2023.04.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Negative symptoms (NS) include asociality, avolition, anhedonia, alogia, and blunted affect and are linked to poor prognosis. It has been suggested that they reflect two different factors: diminished expression (EXP) (blunted affect and alogia) and amotivation/pleasure (MAP) (anhedonia, avolition, asociality). The aim of this article was to examine potential sex differences among first-episode schizophrenia (FES) patients and analyze sex-related predictors of two NS symptoms factors (EXP and MAP) and functional outcome.</div></div><div><h3>Material and methods</h3><div>Two hundred and twenty-three FES (71 females and 152 males) were included and evaluated at baseline, six-months and one-year. Repeated measures ANOVA was used to examine the effects of time and sex on NS and a multiple linear regression backward elimination was performed to predict NS factors (MAP-EXP) and functioning.</div></div><div><h3>Results</h3><div>Females showed fewer NS (<em>p</em> <!-->=<!--> <!-->0.031; Cohen's <em>d</em> <!-->=<!--> <!-->−0.312), especially those related to EXP (<em>p</em> <!-->=<!--> <!-->0.024; Cohen's <em>d</em> <!-->=<!--> <!-->−0.326) rather than MAP (<em>p</em> <!-->=<!--> <!-->0.086), than males. In both male and female group, worse premorbid adjustment and higher depressive symptoms made a significant contribution to the presence of higher deficits in EXP at one-year follow-up, while positive and depressive symptoms predicted alterations in MAP. Finally, in females, lower deficits in MAP and better premorbid adjustment predicted better functioning at one-year follow-up (<em>R</em>² <!-->=<!--> <!-->0.494; <em>p</em> <!-->&lt;<!--> <!-->0.001), while only higher deficits in MAP predicted worse functioning in males (<em>R</em>² <!-->=<!--> <!-->0.088; <em>p</em> <!-->=<!--> <!-->0.012).</div></div><div><h3>Conclusions</h3><div>Slightly sex differences have been found in this study. Our results lead us to consider that early interventions of NS, especially those focusing on motivation and pleasure symptoms, could improve functional outcomes.</div></div>","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 91-99"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135346679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Schizophrenia and the COVID-19 pandemic: A narrative review from the biomedical perspective","authors":"Krzysztof Kowalski,&nbsp;Błażej Misiak","doi":"10.1016/j.rpsm.2023.04.002","DOIUrl":"10.1016/j.rpsm.2023.04.002","url":null,"abstract":"<div><div>The outbreak of the Coronavirus Disease 2019 (COVID-19) pandemic in 2020 caused a rapid worsening of global mental health. Patients with severe mental disorders, including schizophrenia, are at higher risk of being infected. The neuroinvasive potential of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has been confirmed. The aim of this article was to present a narrative and comprehensive review of multidimensional associations between schizophrenia and COVID-19 with special emphasis on common biological pathways. Online searches were performed in the PubMed database and covered the publication period until September 17, 2022. Search terms included “psychosis”, “schizophrenia”, “inflammation” and “COVID-19”. Viewed as a neuroinflammatory state, schizophrenia shares several neurobiological mechanisms with the COVID-19. Environmental stress, common comorbidities of schizophrenia and adverse effects of antipsychotic treatment are associated with the higher severity and mortality of the COVID-19. Additionally, more frequent relapses of psychosis have been observed, and might be related to lower treatment adherence. In the context of clinical manifestation, higher level of negative symptoms has been identified among patients with schizophrenia during the pandemic. Improvements in mental health care policy and treatment adjustment are necessary to protect people with schizophrenia who are the population that is particularly vulnerable to the consequences of the COVID-19 pandemic. Future research will show if prenatal infection with the SARS-CoV-2 increases a risk of psychosis.</div></div>","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 141-148"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9946312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empowering the future of psychiatry: The development of the young psychiatrists section of the Spanish Society of Psychiatry and Mental Health","authors":"Gonzalo Salazar de Pablo ,&nbsp;Claudia Aymerich ,&nbsp;Justo Pinzón-Espinosa","doi":"10.1016/j.sjpmh.2024.09.003","DOIUrl":"10.1016/j.sjpmh.2024.09.003","url":null,"abstract":"","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 149-151"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex and substance use in first episode psychosis: Impact on clinical symptoms, psychosocial functioning and cognitive performance","authors":"Gemma Safont ,&nbsp;Marina Garriga ,&nbsp;Silvia Amoretti ,&nbsp;Manuel J. Cuesta ,&nbsp;Mara Parellada ,&nbsp;Ana González-Pinto ,&nbsp;Daniel Bergé ,&nbsp;Roberto Rodriguez-Jimenez ,&nbsp;Alexandra Roldán Bejarano ,&nbsp;Salvador Sarró ,&nbsp;Ángela Ibáñez ,&nbsp;Judith Usall ,&nbsp;Miguel Gutiérrez ,&nbsp;Eduard Vieta ,&nbsp;Belén Arranz ,&nbsp;Esther Berrocoso ,&nbsp;Norma Verdolini ,&nbsp;Miguel Bernardo ,&nbsp;2EPS Group","doi":"10.1016/j.rpsm.2022.03.002","DOIUrl":"10.1016/j.rpsm.2022.03.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Sex differences in first episode of psychosis (FEP) have been widely studied. However, the existence of controversial results may be attributable to not considering relevant factors such as substance use. Cannabis use is associated with an earlier age of onset of psychosis and rates of cannabis use are consistently higher among men. The main objective of this study was to analyze and describe sex differences while considering the presence of substance use and its potential role when predicting age at onset of psychosis.</div></div><div><h3>Material and methods</h3><div>A cross-sectional study of 223 non-affective FEP patients was performed. Participants were divided into “current substance users”, defined as those who reported having used a substance in the past 30 days, and those who did not as “not current substance users”. Descriptive analyses, general linear modeling and multiple regression modeling were used.</div></div><div><h3>Results</h3><div>In the current substance group, women were older, with an older age of onset, a better premorbid adjustment and a higher cognitive reserve while presenting less clinical severity, a better functioning and a better verbal memory performance in comparison with men. In males, but not in females, lifetime of cannabis use and accumulative lifetime substance use was associated with age of onset.</div></div><div><h3>Conclusions</h3><div>Clinical presentation of FEP varies by sex and especially when considering substance use. Our results suggest that early interventions need to be tailored to the different clinical needs of males and females and according to substance consumption in FEP.</div></div>","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 80-90"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85104668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Luis Martín-Santos: A multidimensional psychiatrist","authors":"José Lázaro","doi":"10.1016/j.sjpmh.2024.09.002","DOIUrl":"10.1016/j.sjpmh.2024.09.002","url":null,"abstract":"","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 70-71"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clozapine use in the first two years after first-episode psychosis in a real-world clinical sample","authors":"Emilio Pechuán ,&nbsp;Alba Toll ,&nbsp;Daniel Bergé ,&nbsp;Teresa Legido ,&nbsp;Laura Martínez-Sadurní ,&nbsp;Amira Trabsa ,&nbsp;Gonzalo De Iturbe ,&nbsp;Sara García Fernández ,&nbsp;Beltran Jiménez-Fernández ,&nbsp;Aurea Fernández ,&nbsp;Víctor Pérez-Solà ,&nbsp;Anna Mané","doi":"10.1016/j.sjpmh.2024.06.001","DOIUrl":"10.1016/j.sjpmh.2024.06.001","url":null,"abstract":"<div><h3>Background</h3><div>Approximately 20–30% of patients with schizophrenia fail to respond to antipsychotic<span> treatment and are considered treatment resistant (TR). Although clozapine is the treatment of choice in these patients, in real-world clinical settings, clinicians often delay clozapine initiation, especially in first-episode psychosis (FEP).</span></div></div><div><h3>Aim</h3><div>The main aim of this study was to describe prescription patterns for clozapine in a sample of patients diagnosed with FEP and receiving specialized treatment at a university hospital. More specifically, we aimed to determine the following: (1) the proportion of patients who received clozapine within two years of disease onset, (2) baseline predictors of clozapine use, (3) time from starting the first antipsychotic to clozapine initiation, (4) concomitant medications, and (5) clozapine-related adverse effects.</div></div><div><h3>Methods</h3><div>All patients admitted to a specialized FEP treatment unit at our hospital between April 2013 and July 2020 were included and followed for two years. The following variables were assessed: baseline sociodemographic characteristics; medications prescribed during follow-up; clozapine-related adverse effects; and baseline predictors of clozapine use. We classified the sample into three groups: clozapine users, clozapine-eligible, and non-treatment resistant (TR).</div></div><div><h3>Results</h3><div>A total of 255 patients were consecutively included. Of these, 20 (7.8%) received clozapine, 57 (22.4%) were clozapine-eligible, and 178 (69.8%) were non-TR. The only significant variable associated with clozapine use at baseline was the Global Assessment of Functioning (GAF) score (<em>R</em>² <!-->=<!--> <!-->0.09, <em>B</em> <!-->=<!--> <!-->−0.07; OR<!--> <!-->=<!--> <!-->0.94; 95% CI: 0.88–0.99; <em>p</em> <!-->=<!--> <span>0.019). The median time to clozapine initiation was 55.0 (93.3) days. The most common side effect was sedation.</span></div></div><div><h3>Conclusions</h3><div>A significant proportion (30.2%) of patients in this cohort were treatment resistant and eligible for clozapine. However, only 7.8% of the sample received clozapine, indicating that this medication was underprescribed. A lower baseline GAF score was associated with clozapine use within two years, suggesting that it could be used to facilitate the early identification of patients who will need treatment with clozapine, which could in turn improve treatment outcomes.</div></div>","PeriodicalId":101179,"journal":{"name":"Spanish Journal of Psychiatry and Mental Health","volume":"18 2","pages":"Pages 125-132"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141441235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}